Compass Therapeutics (NASDAQ:CMPX) 股价上涨 4.5% - 接下来会如何发展？
Compass Therapeutics (NASDAQ:CMPX) shares rose 4.5% to $5.38 during mid-day trading, with a trading volume of approximately 1.66 million shares. Analysts have set a price target of $10.00, with ratings ranging from Strong Buy to Sell. The company reported earnings of ($0.08) per share, beating estimates. Institutional investors hold 68.43% of the stock. Compass Therapeutics focuses on developing immuno-oncology therapies, with lead programs targeting PD-1 and CD47 pathways.
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) shares rose 4.5% during mid-day trading on Tuesday . The stock traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 1,705,218 shares. The stock had previously closed at $5.15.
Get Compass Therapeutics alerts:
Wall Street Analyst Weigh In
- Top 3 High-Momentum Companies Analysts Are Still Bullish On
A number of research analysts have weighed in on the stock. JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an "overweight" rating on the stock. Canaccord Genuity Group started coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a "buy" rating and a $10.00 target price for the company. Citizens Jmp began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a "market outperform" rating and a $10.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.23.
Read Our Latest Research Report on CMPX
Compass Therapeutics Price Performance
The firm has a market cap of $956.89 million, a price-to-earnings ratio of -11.96 and a beta of 1.44. The business has a 50-day moving average of $4.81 and a 200-day moving average of $3.78.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. As a group, equities analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.
Hedge Funds Weigh In On Compass Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in Compass Therapeutics in the 3rd quarter valued at $35,000. CIBC Bancorp USA Inc. acquired a new stake in Compass Therapeutics during the 3rd quarter valued at $37,000. Creative Planning bought a new position in Compass Therapeutics during the second quarter worth $30,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after purchasing an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.
Compass Therapeutics Company Profile
(Get Free Report)Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.
Featured Articles
- Five stocks we like better than Compass Therapeutics
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Compass Therapeutics Right Now?
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
